Search Result

Results for "

quinazoline

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (9) Akt (1) Apoptosis (2) Autophagy (1) Bacterial (2) COX (1) Cytochrome P450 (3) EGFR (5) Fungal (3) GCGR (1) Glucosidase (1) HDAC (1) Histone Methyltransferase (2) Interleukin Related (1) Isotope-Labeled Compounds (2) JAK (1) JNK (1) Leukotriene Receptor (1) Mitochondrial Metabolism (1) Mitophagy (1) NAMPT (1) NF-κB (1) NO Synthase (2) Parasite (1) PARP (1) PD-1/PD-L1 (4) PI3K (2) Potassium Channel (1) PROTACs (1) Ras (1) TNF Receptor (1) VEGFR (1)
By Research Areas:	Cancer (18) Cardiovascular Disease (4) Endocrinology (7) Infection (5) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (4)

By Targets:

Adrenergic Receptor (9)

Akt (1)

Apoptosis (2)

Autophagy (1)

Bacterial (2)

COX (1)

Cytochrome P450 (3)

EGFR (5)

Fungal (3)

GCGR (1)

Glucosidase (1)

HDAC (1)

Histone Methyltransferase (2)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

JAK (1)

JNK (1)

Leukotriene Receptor (1)

Mitochondrial Metabolism (1)

Mitophagy (1)

NAMPT (1)

NF-κB (1)

NO Synthase (2)

Parasite (1)

PARP (1)

PD-1/PD-L1 (4)

PI3K (2)

Potassium Channel (1)

PROTACs (1)

Ras (1)

TNF Receptor (1)

VEGFR (1)

By Research Areas:

Cancer (18)

Cardiovascular Disease (4)

Endocrinology (7)

Infection (5)

Inflammation/Immunology (3)

Metabolic Disease (4)

Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1100

Vasicinone (-)-Vasicinone	Others	Neurological Disease
Vasicinone is a quinazoline alkaloid isolated from the Adhatoda vasica. Vasicinone is a potential agent for Parkinson's disease and possibly other oxidative stress-related neurodegenerative disorders .

HY-101931

hVEGF-IN-1	VEGFR	Cancer
hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a K_d of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression .

HY-106554

Trimazosin	Adrenergic Receptor	Cardiovascular Disease
Trimazosin is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows hypotensive effect by selectively block α1-adrenoceptors .

HY-12122

AR-C102222	NO Synthase	Neurological Disease
AR-C102222 is a spirocyclic fluoropiperidine quinazoline selective iNOS inhibitor. AR-C102222 can be used for the research of neuropathic pain .

HY-B0371

Terazosin	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0371F

Terazosin hydrochloride 4 Publications Verification	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0371A

Terazosin hydrochloride dihydrate 4 Publications Verification	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-N6607

Tryptanthrin 2 Publications Verification	Leukotriene Receptor NO Synthase NF-κB COX TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α .

HY-N1103

Vasicine Peganine	Bacterial	Inflammation/Immunology
Vasicine (peganine) is a quinazoline alkaloid isolated from Justicia adhatoda. Vasicine (peganine) possesses anti- tuberculosis activity .

HY-B0098A

Doxazosin mesylate 1 Publications Verification UK 33274 mesylate	Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology Cancer
Doxazosin mesylate (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

HY-B0098

Doxazosin UK 33274	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Doxazosin (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

HY-156287

GCase modulator-1

Glucosidase Cancer

GCase modulator-1 (compound 9g), a derivative of Quinazoline, is a modulator of GCase (Glucosidase) (AC₅₀=2.23 μM) .
HY-163421

hERG-IN-2

Potassium Channel Cancer

hERG-IN-2 (Compound 1) is a potent hERG inhibitor, with an IC₅₀ of < 2 μM. hERG-IN-2 can be used for the research of cancer .

GCase modulator-1	Glucosidase	Cancer
GCase modulator-1 (compound 9g), a derivative of Quinazoline, is a modulator of GCase (Glucosidase) (AC₅₀=2.23 μM) .

hERG-IN-2	Potassium Channel	Cancer
hERG-IN-2 (Compound 1) is a potent hERG inhibitor, with an IC₅₀ of < 2 μM. hERG-IN-2 can be used for the research of cancer .

HY-B0098S

Doxazosin-d8 UK 33274 d₈	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Endocrinology
Doxazosin-d₈ is a deuterium labeled Doxazosin (UK 33274). Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1 adrenergic receptors[1].

HY-131449

Terazosin dimer impurity dihydrochloride	Adrenergic Receptor	Others
Terazosin dimer impurity dihydrochloride, a dimer of Terazosin, is an impurity of Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist .

HY-148273

Setidegrasib KRAS G12D inhibitor 17	PROTACs Ras	Cancer
Setidegrasib (example 8) is a quinazoline-linked (4R)-4-hydroxy-L-prolinamide compound, inducing degradation of G12D-mutation KRAS protein. Setidegrasib is a PROTAC .

HY-14375

CB 300919	NAMPT	Cancer
CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC₅₀ value of 2 nM in human CH1 ovarian tumor xenograft .

HY-108419

WHI-P258	JNK	Cancer
WHI-P258, a quinazoline compound, binds to the active site of JAK3 with an estimated K_i of 72 µM. WHI-P258 does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM .

HY-147967

EGFR-IN-63

EGFR Cancer

EGFR-IN-63 is an EGFR inhibition (IC₅₀: 0.096 μM) and it has anticancer activity in MCF-7 cells (IC₅₀: 2.49 μM).

EGFR-IN-63	EGFR	Cancer
EGFR-IN-63 is an EGFR inhibition (IC₅₀: 0.096 μM) and it has anticancer activity in MCF-7 cells (IC₅₀: 2.49 μM).

HY-15375

Allitinib AST-1306; ALS 1306	EGFR	Cancer
Allitinib (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC₅₀s of 0.5 and 3 nM, respectively. Allitinib also inhibits ErbB4 with an IC₅₀ of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity .

HY-13427

Allitinib tosylate AST-1306 (TsOH)	EGFR	Cancer
Allitinib tosylate (AST-1306 (TsOH)) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC₅₀s of 0.5 and 3 nM, respectively. Allitinib tosylate also inhibits ErbB4 with an IC₅₀ of 0.8 nM. Allitinib tosylate is an anilino-quinazoline compound and has anti-cancer activity

HY-N2106

Dehydroevodiamine
Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes . Dehydroevodiamine inhibits LPS-induced iNOS, COX-2, prostaglandin E2 (PGE2) and nuclear factor-kappa B (NF-κB) expression in murine macrophage cells .

HY-B0371S

Terazosin-d8	Isotope-Labeled Compounds Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

HY-155107

ND-011992	Mitochondrial Metabolism Bacterial	Infection
ND-011992 is a reversible, selective quinazoline-type inhibitor targeting quinone reductases and quinol oxidases. ND-011992 inhibits respiratory complex I and bo₃ oxidase in addition to bd-I and bd-II oxidases in E. coli strain BL21Δcyo with the IC₅₀* of 0.12, 2.47, 0.63 and 1.3 μM, respectively. ND-011992 can be used for tuberculosis study .

HY-144075

JAK-IN-19	JAK	Inflammation/Immunology
JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC₅₀=7.2 and HLF Eotaxin pIC₅₀=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC₅₀=7.0, Aurora B pIC₅₀=5.8) .

HY-157413

YS-67	EGFR	Cancer
YS-67 is a potent inhibitor of EGFR with an IC ₅₀ of 5.2 nM. YS-67 significantly inhibits p-EGFR and p-AKT. YS-67 inhibits the proliferation of A549, PC-9, and A431cells with IC ₅₀s of 4.1, 0.5, and 2.1 μM, respectively .

HY-151387

A2AAR antagonist 1	Others	Neurological Disease
A2AAR antagonist 1 (compound 21a) is an A2AAR (adenosine A2A receptor) antagonist with a K_i value of 20 nM. A2AAR antagonist 1 shows high ligand efficiency, and it can be used for the research of neurodegenerative diseases .

HY-143472

PI3Kδ-IN-11	PI3K Akt Apoptosis	Cancer
PI3Kδ-IN-11 is a highly potent and selective PI3Kδ inhibitor with IC₅₀ value of 27.5 nM. PI3Kδ-IN-11 dose-dependently blocks the activity of PI3K/Akt pathway. PI3Kδ-IN-11 can be used for researching B or T cell-related malignancies .

HY-162349

PARP7/HDACs-IN-1	HDAC PARP	Cancer
PARP7/HDACs-IN-1 (compound 9l) is a dual-target inhibitor targeting PARP7/HDAC with anti-tumor activity. PARP7/HDACs-IN-1 inhibits different subtypes of PARPs and HDACs with IC₅₀s of 83.3 nM (PARP1), 3.1 nM (PARP7), 35 nM (HDAC1), 30.3 nM (HDAC2), 35.4 nM (HDAC3), and 6.4 nM respectively. (HDAC6) . br/ .

HY-10929

UNC0224 1 Publications Verification	Histone Methyltransferase	Cancer
UNC0224 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 2.6 nM, an IC₅₀ of 15 nM and a K_d of 23 nM. UNC0224 also potently inhibits b>GLP with assay-dependent IC₅₀ values of 20-58 nM. UNC0224 is inactive against SET7/9, SET8/PreSET7, PRMT3 and JMJD2E .

HY-10930

UNC0321 2 Publications Verification	Histone Methyltransferase GCGR Apoptosis	Cancer
UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 63 pM and with assay-dependent IC₅₀ values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC₅₀ values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications .

HY-144649

PD-1/PD-L1-IN-24	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-24 is a highly potent PD-1/PD-L1 inhibitor with IC₅₀ value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs .

HY-156150

CYP51/PD-L1-IN-2	Fungal Cytochrome P450 PD-1/PD-L1	Infection
CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC₅₀: 0.263 μM) and PD-L1 (IC₅₀: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .

HY-156151

CYP51/PD-L1-IN-3	Fungal Cytochrome P450 PD-1/PD-L1	Infection
CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC₅₀: 0.205 μM) and PD-L1 (IC₅₀: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .

HY-156149

CYP51/PD-L1-IN-1	Fungal Cytochrome P450 PD-1/PD-L1	Infection
CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC₅₀: 0.884 μM) and PD-L1 (IC₅₀: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .

HY-107364

MTX-211 2 Publications Verification Mol 211	EGFR PI3K	Cancer
MTX-211 (Mol 211) is a dual inhibitor of EGFR and PI3K with IC₅₀ values of ＜100 nM. MTX-211 can be used for the research of cancer and other diseases .

HY-147371

Quinoprazine	Parasite	Infection Neurological Disease
Quinoprazine is a potent inhibitor of Vaccinia virus DNA synthesis with an IC₅₀ value of 10 μM. Quinoprazine has antimalarial activity against Plasmodium berghei and also displays antiprion potency, significantly decreases PrP ^{S ^c} levels ^- .

Cat. No.	Product Name	Category	Target	Chemical Structure